QUALITY BY DESIGN APPROACH FOR DEVELOPMENT AND OPTIMIZATION OF CHITOSAN-BASED FLOATING MICROSPHERES FOR TOPOTECAN HCl-Reference-Cited by-同舟云学术

QUALITY BY DESIGN APPROACH FOR DEVELOPMENT AND OPTIMIZATION OF CHITOSAN-BASED FLOATING MICROSPHERES FOR TOPOTECAN HCl

Published:2023-11-07 Issue: Volume: Page:153-162
ISSN:0975-7058
Container-title:International Journal of Applied Pharmaceutics
language:
Short-container-title:Int J App Pharm

Author:

PRAGALLAPATI PRAHLAD^ORCID,LAKSHMI PONNURI REVATHI NAGA^ORCID,MURTHY KOLLAPALLI VENKATA RAMANA^ORCID

Abstract

Objective: To develop floating microspheres for the topotecan in order to prevent its onversion into inactive carboxylate form in intestinal pH conditions so as to improve its bioavailability. Methods: Chitosan-based porous floating microspheres containing sodium bicarbonate by coacervation technique were developed. Quality by design approach using Box-Behnken Design was adopted to assess the influences of selected formulation variables and their importance on the quality of the finished product. Results: The selected model was analyzed and optimized. The microspheres floated immediately without any lag time upon addition into water and remained floatable for more than 24 h-1. The optimized formulation was found to have the particle size of 379.2 µm, entrapment efficiency of 76.3% and the drug release rate constant of 0.29 h i.e., the release was extended up to 16 h-1. Conclusion: The results affirmed that controlled-release porous microspheres of Topotecan with inherent floating without lag were successfully developed.

Publisher

Innovare Academic Sciences Pvt Ltd

Subject

Pharmaceutical Science

Reference32 articles.

1. Swamy MK, Nath S, Paul S, Jha NK, Purushotham B, Rohit KC. Biotechnology of camptothecin production in Nothapodytes nimmoniana, Ophiorrhiza sp. and Camptotheca acuminata. Appl Microbiol Biotechnol. 2021 Dec;105(24):9089-102. doi: 10.1007/s00253-021-11700-5, PMID 34850279.

2. Laham Karam N, Pinto GP, Poso A, Kokkonen P. Transcription and translation inhibitors in cancer treatment. Front Chem. 2020 Apr 21;8:276. doi: 10.3389/fchem.2020.00276, PMID 32373584.

3. Oliveira EA, Chauhan J, Silva JRD, Carvalho LADC, Dias D, Carvalho DG. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacol Res. 2021;173:105911. doi: 10.1016/j.phrs.2021.105911. PMID 34560251.

4. From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018 Aug;13(6):612-32. doi: 10.1177/1747493018778713, PMID 29786478.

5. Mills H, Acquah R, Tang N, Cheung L, Klenk S, Glassen R. A critical scrutiny on liposomal nanoparticles drug carriers as modelled by topotecan encapsulation and release in treating cancer. Evid Based Complement Alternat Med. 2022 Aug 9;2022:7702512. doi: 10.1155/2022/7702512, PMID 35983007.